Jim Gaffigan has a sleek new look to match his recent Hollywood renaissance, which includes his hilarious turn on SNL as vice ...

Comedian Jim Gaffigan is the first to admit his weight has fluctuated over the years. After reaching 270 lbs., he decided to ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Jim Gaffigan has always used his weight and love for eating as a punchline in his comedy, even going so far to title his 2013 ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Jim Gaffigan exclusively told Us Weekly about using the weight loss drug Mounjaro and why food addiction gets "less sympathy" ...